Dr Stilgenbauer’s research focus is on the molecular pathogenesis and evolution as well as the development of novel treatment strategies in hematological malignancies.

He received his medical training at Heidelberg Medical School, Germany, and was trained in internal medicine and hematology-oncology at the Universities of Heidelberg and Ulm. He spent a postdoctoral fellowship at the German Cancer Research Center (DKFZ) in Heidelberg.

Dr Stilgenbauer has authored or coauthored numerous original articles, reviews and book chapters in journals including the The New England Journal of Medicine, The Lancet, Nature, Nature Medicine, Proc Natl Acad Sci USA, Journal of Clinical Oncology, Blood, Leukemia, Haematologica. He has contributed to the approval of several novel treatment principles such as rituximab, obinutuzumab, idelalisib, duvelisib, ibrutinib, acalabrutinib and venetoclax.